It's taken decades, but there is finally a vaccine to protect against serious disease from #RSV. This one's for adults 60 and older, from #GSK. Options for protecting infants coming later this year. https://t.co/MEv0CrfrtR
The use of #AI for pandemic and outbreak infectious disease surveillance, a review @NEJM today
https://t.co/Khn0ldv2VD @johnbrownstein@AstleyCM and colleagues
Our new study in @CDCMMWR on use of at-home #covid tests
Online survey of 400k+ U.S. adults (08/21-03/22)
At-home testing rose rapidly with #omicron
Most common among White adults, ages 30-39 and income >$150k
Highlights the need for equitable access
https://t.co/9awKnOnWLs
1/
We've just confirmed the effectiveness of the Pfizer-BioNTech vaccine outside of randomized trials.
Details @NEJM: https://t.co/POgXK8owvM
Yes, great news, but let's talk about methodological issues that arise when using #observational data to estimate vaccine effectiveness.
via @NYTOpinion Op-ed with @adamhfinn on altering vaccine strategy, provide first doses to all those at highest risk now, worry about second doses later. https://t.co/9BS4LIeHRc
Important notes
Mask mandates alone were not sufficient to increase mask wearing.
Mask wearing layered with social distancing yielded highest probability of transmission control.
Findings remained strong after accounting for other factors (eg mobility and pop density).
Back-to-school survey shows remote or in person similar Grades 1 to college -- despite huge differences in development.
Are we trying to make one plan fit all for back-to-school?
@laurawronski@johnbrownstein@meiralevinson@mlipsitch
https://t.co/k6X4OB9sor
Differential geographic accessibility to SARS-CoV-2 testing by region, population density, percent minority, uninsured. This may worsen healthcare disparities and bias COVID-19 transmission estimates. https://t.co/3t9oC6hyKD @johnbrownstein@MOUGK#covid19#spatial